Hikma warns SCOTUS of ‘imminent threat’ for generic competition under ‘skinny label’ rules

British pharma giant says that a Federal Circuit decision could stifle competition by lowering the bar for proving patent infringement | Earlier ruling ‘nullifies a statutory mechanism for expediting access to generic drugs and breaks sharply with precedent on inducement’ says UK pharma company.